Related references
Note: Only part of the references are listed.Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents
So Takata et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan et al.
CANCER (2019)
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
Tri Le et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Can nivolumab be used safely in idiopathic pulmonary fibrosis?
B. Duchemann et al.
REVUE DES MALADIES RESPIRATOIRES (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
Kohei Fujita et al.
RESPIRATORY MEDICINE (2019)
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
Qiang Su et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L. Barber et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy
Mizuki Nishino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients Efficacy and Safety of Combination
Francesco Fiorica et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
H. Picchi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
Guillaume Louvel et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Immunotherapy: a new standard of care in thoracic malignancies?
Adrien Costantini et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer
Harper G. Hubbeling et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai et al.
THORACIC CANCER (2018)
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
N. Koyama et al.
BMC PULMONARY MEDICINE (2018)
Lung cancer and interstitial lung disease: a literature review
Jean-Marc Naccache et al.
JOURNAL OF THORACIC DISEASE (2018)
Patients with IPF and lung cancer: diagnosis and management
Argyris Tzouvelekis et al.
LANCET RESPIRATORY MEDICINE (2018)
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
William L. Hwang et al.
JAMA ONCOLOGY (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
Jun Yeun Cho et al.
LUNG CANCER (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors
G. Faviez et al.
REVUE DES MALADIES RESPIRATOIRES (2018)
Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma
Eduard Teixidor et al.
Oncotarget (2018)
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
Maako Ide et al.
THORACIC CANCER (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma
Michael A. Mitchell et al.
IMMUNOTHERAPY (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report
Wan He et al.
ONCOTARGETS AND THERAPY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
Paul Lesueur et al.
CANCER MEDICINE (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey
Thierry Berghmans et al.
ERJ OPEN RESEARCH (2018)
Sarcoid-Like Granulomatosis Induced by Nivolumab Treatment in a Lung Cancer Patient
Susumu Noguchi et al.
CASE REPORTS IN ONCOLOGY (2018)
PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
J. Vansteenkiste et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study
Daniel Franzen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Pulmonary sarcoid-like granulomatosis induced by nivolumab
H. Montaudie et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
Ricardo Costa et al.
ONCOTARGET (2017)
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer
Linda Mahjoubi et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
Tsukasa Ishiwata et al.
INTERNAL MEDICINE (2017)
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
Andrew Bang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Pulmonary Infiltrates in a Patient With Advanced Melanoma
Charles A. Powell
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy
Hisashi Nomura et al.
JOURNAL OF DERMATOLOGY (2017)
Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti–PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma
Yi-Chun Chu et al.
Journal of Thoracic Oncology (2017)
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
Monica Khunger et al.
Journal of Thoracic Oncology (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia
Daichi Fujimoto et al.
LUNG CANCER (2017)
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
Maximilian J. Hochmair et al.
LUNG CANCER (2017)
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Terufumi Kato et al.
LUNG CANCER (2017)
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
Amelie Aboudaram et al.
MELANOMA RESEARCH (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation
Luke R. G. Pike et al.
RADIOTHERAPY AND ONCOLOGY (2017)
EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer
Segolene Lainez et al.
RESPIRATION (2017)
Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy
Jerome Doyen et al.
JAMA DERMATOLOGY (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
Christopher S. King et al.
LANCET RESPIRATORY MEDICINE (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy
A. V. Tallet et al.
ANNALS OF ONCOLOGY (2017)
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis
Yang-Bo Hu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment
T. Yanagihara et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab induced radiation recall pneumonitis after two years of radiotherapy
R. Shibaki et al.
ANNALS OF ONCOLOGY (2017)
HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome
Rachel P. J. Lai et al.
SEMINARS IN IMMUNOPATHOLOGY (2016)
Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma
Joycelyn J. X. Lee et al.
ACTA ONCOLOGICA (2016)
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
K. A. Ahmed et al.
ANNALS OF ONCOLOGY (2016)
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
Francois-Xavier Danlos et al.
CHEST (2016)
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Sophie Cousin et al.
CLINICAL CANCER RESEARCH (2016)
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
Maria Del Castillo et al.
CLINICAL INFECTIOUS DISEASES (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Nivolumab-induced organizing pneumonia in a melanoma patient
Tasuku Sano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Kohei Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
V. Gounant et al.
LUNG CANCER (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
E. Liniker et al.
ONCOIMMUNOLOGY (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Joshua E. Reuss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
Kevin P. Murphy et al.
Oncology Research and Treatment (2016)
Decreased Cytotoxic T-Lymphocyte Antigen 4 Expression on Regulatory T Cells and Th17 Cells in Sarcoidosis: Double Trouble?
Caroline E. Broos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Sarcoidosis and Cancer Risk Systematic Review and Meta-analysis of Observational Studies
Martina Bonifazi et al.
CHEST (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
Valsamo K. Anagnostou et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Unusual pulmonary toxicity of ipilimumab treated by macrolides
M. Mailleux et al.
ACTA CLINICA BELGICA (2015)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Igor Z. Barjaktarevic et al.
CHEST (2013)
Sarcoidosis complicating anti-cytotoxic T-Iymphocyte-associated antigen-4 monoclonal antibody biotherapy
Claire Tissot et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
Ross B. Reule et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Gregoire Berthod et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
Wouter V. Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
Ulrich Costabel et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
A. Eckert et al.
DERMATOLOGY (2009)
Clinical characteristics of patients in a case control study of sarcoidosis
RP Baughman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
CT of parenchymal and bronchial tuberculosis
C Beigelman et al.
EUROPEAN RADIOLOGY (2000)
Share Paper
